joins
In a significant reform aimed at simplifying and catalysing corporate restructuring, the Fast Track Merger (FTM) route under Section 233 of the Companies Act, 2013, has been strengthened and expanded....
In the past couple of months, the healthcare and pharmaceutical sectors have undergone significant regulatory and policy shifts, highlighting a sustained focus on transparency, quality assurance, and industry facilitation. A key development during this period has been the introduction of the Pharmacy Council of India (Manner of Holding Inquiry and Imposition of Penalty) Regulations, 2025, bringing long-needed procedural clarity to disciplinary proceedings under the Pharmacy Act, 1948. This move aims to harmonise the framework for conducting inquiries and levying penalties across state pharmacy councils and plug long-standing procedural gaps.
On the pharmaceutical front, the Central Drugs Standard Control Organisation has mandated exclusive use of the Online National Drugs Licensing System portal for procurement of World Health Organisation Good Manufacturing Practices Certificate and Certificate of Pharmaceutical Products – an important step toward digitization and simplification of compliance processes. In parallel, medical device reforms, from eased sterilisation norms to updated skill development guidelines, reflect a push for operational efficiency and capacity-building.
In this edition of ‘Checking the Pulse’, CMS INDUSLAW’s Shantanu Jindel, Shweta Gupta, Kanika Sachdeva, Vatsal Agarwal, Abhinav A delve into the key updates in the healthcare and pharmaceutical sectors pertaining to the months of June 2025 and July 2025.
